Representative Engagements
Class II Medical Device Manufacturer Prepares for First FDA Inspection
Situation
A mid-sized medical device manufacturer was preparing for their first FDA inspection in over three years. Internal audits had revealed gaps in CAPA effectiveness, design control documentation, and supplier management practices. The quality team was understaffed and uncertain about inspection protocol.
Approach
We conducted a comprehensive pre-inspection audit using FDA investigator techniques, identified high-risk areas, and developed a detailed remediation plan. We facilitated cross-functional teams to close critical gaps, coached leadership on inspection management, and conducted mock inspection sessions to prepare staff for investigator interactions.
Outcome
The FDA inspection resulted in zero 483 observations. The manufacturer gained confidence in their quality systems and established sustainable practices for ongoing compliance monitoring.
Established Manufacturer Resolves Multiple 483 Observations
Situation
Following an FDA inspection, a manufacturer received a 483 with six observations related to CAPA effectiveness, process validation deficiencies, and inadequate complaint handling procedures. The company faced pressure from distributor partners and potential Warning Letter escalation if the response was insufficient.
Approach
We led the root cause analysis for each observation, developed comprehensive corrective and preventive actions, and prepared a detailed written response with supporting evidence. We implemented process improvements, retrained staff, and established metrics to demonstrate sustainable correction.
Outcome
FDA accepted the 483 response without further action. The company strengthened their quality culture, improved cross-functional collaboration, and implemented proactive monitoring systems to prevent future observations.
IVD Startup Implements ISO 13485-Compliant QMS
Situation
An early-stage IVD company had developed a promising diagnostic platform but lacked a formal quality management system. With their first 510(k) submission approaching, they needed to establish compliant QMS infrastructure, design history files, and validation protocols to support their regulatory pathway.
Approach
We designed and implemented a scalable ISO 13485-compliant QMS tailored to their stage and resources. This included establishing design controls, risk management processes, document control systems, and supplier qualification protocols. We trained their team on day-to-day QMS maintenance and prepared comprehensive design history files.
Outcome
The company successfully submitted their 510(k) with complete DHF documentation and received FDA clearance. The QMS infrastructure scaled effectively as the company grew, supporting subsequent product launches and investor due diligence.
Novel Device Manufacturer Navigates De Novo Classification
Situation
A medical device company developing a novel technology faced uncertainty about the appropriate regulatory pathway. Without a clear predicate device, they needed to determine whether De Novo classification was appropriate and develop a strategy for FDA engagement and submission preparation.
Approach
We conducted a comprehensive device classification analysis, evaluated the De Novo pathway feasibility, and prepared the company for pre-submission meetings with FDA. We developed a clinical evidence strategy, coordinated with their product development team, and guided submission documentation to address FDA's expected review criteria.
Outcome
The company successfully achieved De Novo classification and market authorization. The strategic approach to FDA engagement established a positive working relationship and positioned the company for future product development.
Medical Device Manufacturer Resolves FDA Warning Letter
Situation
A manufacturer received a Warning Letter following an FDA inspection with systemic quality system deficiencies. The company faced significant business impact including delayed shipments, distributor concerns, and potential consent decree if remediation was not adequate and timely.
Approach
We developed a comprehensive response strategy addressing root causes and systemic improvements. We coordinated management commitment, executed corrective and preventive actions, implemented process redesigns, and established ongoing compliance monitoring. We prepared detailed documentation and managed FDA communication throughout the process.
Outcome
FDA accepted the remediation plan and closed the Warning Letter. The company implemented lasting quality system improvements and established a proactive compliance culture that positioned them for sustainable FDA compliance.
PE-Backed Portfolio Company Strengthens QA/RA Function
Situation
A recently acquired medical device company lacked dedicated senior-level quality and regulatory leadership. The private equity owners needed compliance oversight, strategic guidance for upcoming regulatory submissions, and a plan to build out the QA/RA function to support growth.
Approach
We provided fractional QA/RA leadership, conducting a comprehensive compliance assessment and developing a priority-based improvement plan. We delivered ongoing advisory support for regulatory submissions, quality system enhancements, and compliance monitoring. We also provided executive-level reporting to the board and investors.
Outcome
The company achieved stabilized compliance posture, successfully navigated regulatory inspections and submissions, and developed internal QA/RA capabilities to support continued growth and eventual exit strategy.
Note: These case examples use placeholder descriptions to represent the types and scope of our engagements. Specific client names, quantified outcomes, and detailed engagement descriptions have been kept confidential at the clients request.